LivingGLP1
parallel randomized trial

S003441

Type 2 diabetes (adults)S003441

Design

Randomized
Start year
Treatment
52.18 weeks, follow-up 52.18 weeks
Countries
Russia (1 sites)
Sponsor
(not reported)
Eligibility
T2D with obesity, 18 to 75 years; no insulin; eGFR 30 or above

Conduct and analysis

Blinding
not reported
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Dulaglutide 1.5 mg subcutaneous once weekly
Dulaglutide 1.5 mg plus metformin
metformin; lifestyle: standard57
A2Metformin
Metformin monotherapy 1.5 to 2.0 g daily
lifestyle: standard53

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticDulaglutide 1.5 mg subcutaneous once weekly
A1
Metformin
A2
agemedian (years)5960
ageq1 (years)3741
ageq3 (years)7375
bmimedian (kg/m2)39.236.6
bmiq1 (kg/m2)3429.2
bmiq3 (kg/m2)44.843.6
femalen3931
hba1cmedian (percent)7.27.1
hba1cq1 (percent)6.56.3
hba1cq3 (percent)9.38.2
other hypertensionn4636
other ischemic heart diseasen162
other prior stroken5
waistmedian (cm)125118
waistq1 (cm)11597
waistq3 (cm)135137
weightmedian (kg)109105
weightq1 (kg)9357
weightq3 (kg)131123

Results

5 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (2 lines; O01)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
52.18A1final percentnot stated; other; R0049243:Table 2
52.18A2final percentnot stated; other; R0049243:Table 2
Body weight change in kilograms (diabetes) (3 lines; O02)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
52.18A1change kgnot stated; other; R0049243:Discussion
52.18A1final kgnot stated; other; R0049243:Table 2
52.18A2final kgnot stated; other; R0049243:Table 2